FOLD News and Press, Amicus Therapeutics Inc. From 01/07/24

2023 Total Revenue of ~$399.4M, a 21% Increase Year-Over-Year >2,400 People Living with Fabry Disease on Galafold ® Following a Year of Increased Demand Expecting 2024 Galafold Revenue Growth of 11-16% at CER Successful Launche...

PRINCETON, N.J., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that Bradley Campbell, President and Chief Executive Officer, will present at the 42 nd Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Monday, January 8, 2024, at 2:15 p.m. ...

2023-12-27 12:29:36 ET More on AbbVie, Johnson & Johnson, etc. Pfizer: Why I Am Buying The 5.92% Yield After The 2.4% Dividend Increase Eli Lilly: Consider Cutting Before The Southbound Train Leaves (Rating Downgrade) AbbVie Vs. GSK: Dual Dominance In Pharma ...

2023-12-09 01:30:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2023-12-06 07:11:27 ET More on Pfizer Johnson & Johnson Vs. Pfizer: Better Pharma Stock? Pfizer: This Year's Disaster Should Set The Stage For A Strong 2024 Pfizer: Slimming Down After COVID Franchise And Obesity Pipeline Setbacks Seagen gains amid option...

Crowley to Step Down from Amicus Board of Directors in March 2024 and Become Amicus Chairman Emeritus Michael Raab, Current Lead Independent Director, to Become Chairman of Amicus Board of Directors PRINCETON, N.J., Dec. 05, 2023 (GLOBE NEWSWIRE) -- Amicus Ther...

2023-11-08 18:02:41 ET More on Amicus Therapeutics Amicus Therapeutics Q3 2023 Earnings Call Transcript Amicus Therapeutics: The Right Play Now Amicus Therapeutics: Limited Label For Pombiliti And Opfolda And Why It May Not Matter Amicus Therapeutics beats Q3...

2023-11-08 14:59:09 ET Amicus Therapeutics Inc. (FOLD) Q3 2023 Earnings Conference Call November 08, 2023, 08:30 AM ET Company Participants Andrew Faughnan - Vice President, Investor Relations Bradley Campbell - President, Chief Executive Officer Sebastien Martel...

2023-11-08 07:06:18 ET More on Amicus Therapeutics Amicus Therapeutics: The Right Play Now Amicus Therapeutics: Limited Label For Pombiliti And Opfolda And Why It May Not Matter Amicus: Holding Until AT-GAA U.S. Approval Amicus in pact with Blackstone for $43...

3Q 2023 Total Revenue of $103.5M, a 27% Increase Year-Over-Year and 22% at CER Galafol d ® Quarterly Revenue Surpasses $100M for the First Time Increasing FY 2023 Galafol d ® Revenue Growth Guidance to 16%...